IL6 and COVID-19: The role of inflammation as a pathogenetic factor of COVID-19-associated morbidity and mortality has hence been studied both from a molecular and from a clinical-practice point of view, using anti-inflammatory therapies, such as glucocorticoids and IL-6 inhibitors, and reporting their improving effects on mortality and organ complications in severe COVID-19 patients [76,77,78,79].